“Assessing the Benefits of Rosiglitazone in Women With Polycystic Ovary Syndrome through Its Effects on Insulin-Like Growth Factor 1, Insulin-Like Growth Factor-Binding Protein-3 and Insulin Resistance: A Pilot Study”. Clinics, vol. 67, no. 3, Jan. 2012, pp. 283-7, https://doi.org/10.6061/clinics/2012(03)14.